A genetic polymorphism in P2RY 1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy

Código QR

A genetic polymorphism in P2RY 1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy

Abstract Clopidogrel is converted to its active metabolite by cytochrome P450 isoenzymes and irreversibly inhibits platelet activation by antagonizing the adenosine-diphosphate (ADP) receptor. It is frequently used in cats with hypertrophic cardiomyopathy (HCM) to prevent thromboembolic complication...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu Ueda, Ronald H. L. Li, Nghi Nguyen, Eric S. Ontiveros, Samantha L. Kovacs, Maureen S. Oldach, Karen M. Vernau, Michael H. Court, Joshua A. Stern
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ddb2a51e34504216b33792c1c628f25d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Analysis of the Serum Peptidomics Profile for Cats With Sarcomeric Gene Mutation and Hypertrophic Cardiomyopathy
por: Pratch Sukumolanan, et al.
Publicado: (2021)

Management of Hypertrophic Cardiomyopathy
por: Alan D. Enriquez, et al.
Publicado: (2014)

Hypertrophic Cardiomyopathy with a Twist
por: W. Francis, et al.
Publicado: (2021)

Hypertrophic Cardiomyopathy in South Western Nigeria
por: Amam Mbakwem, et al.
Publicado: (2017)

Feline hypertrophic cardiomyopathy: an echocardiographic approach
por: Silva,AC, et al.
Publicado: (2013)

COVID-19 in Adults With Hypertrophic Cardiomyopathy
por: Milla E. Arabadjian, et al.
Publicado: (2021)

Sex differences in the prognosis of patients with hypertrophic cardiomyopathy
por: Minkwan Kim, et al.
Publicado: (2021)

Hypertrophic cardiomyopathy: a modern view of the problem
por: Amina M. Alieva, et al.
Publicado: (2020)

Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy
por: Styliani Vakrou, et al.
Publicado: (2021)

Distinct Metabolomic Signatures in Preclinical and Obstructive Hypertrophic Cardiomyopathy
por: Maike Schuldt, et al.
Publicado: (2021)

Targeted exome analysis of Russian patients with hypertrophic cardiomyopathy
por: Elena V. Filatova, et al.
Publicado: (2021)

ABCB1 polymorphism in clopidogrel-treated Montenegrin patients
por: Mugosa Snezana, et al.
Publicado: (2021)

Loss of embryonic neural crest derived cardiomyocytes causes adult onset hypertrophic cardiomyopathy in zebrafish
por: Sarah Abdul-Wajid, et al.
Publicado: (2018)

Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response
por: Kreutz RP, et al.
Publicado: (2013)

Clinical predictors of the presence of obstructive sleep apnea in patients with hypertrophic cardiomyopathy
por: Haobo Xu, et al.
Publicado: (2021)

Identification of key proteins and lncRNAs in hypertrophic cardiomyopathy by integrated network analysis
por: Xiaofeng Hu, et al.
Publicado: (2019)

Left ventricular non-compaction with hypertrophic cardiomyopathy, a mutually beneficial combination?
por: Vijayaraghavan Govindan, et al.
Publicado: (2021)

Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response
por: Li L, et al.
Publicado: (2012)

Correlations between low thyroid function and incidence of atrial fibrillation in hypertrophic obstructive cardiomyopathy
por: Li-Min Liu, et al.
Publicado: (2020)

Prevalence, functional characteristics, and clinical significance of right ventricular involvement in patients with hypertrophic cardiomyopathy
por: Jiwon Seo, et al.
Publicado: (2020)

Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes
por: Bradley A. Maron, et al.
Publicado: (2021)

Correlation of miR-146a-5p plasma levels and rs2910164 polymorphism with left ventricle outflow tract obstruction in hypertrophic cardiomyopathy
por: Dimitrios Ntelios, et al.
Publicado: (2021)

Efficacy and safety of alcohol septal ablation in patients over 65 years old with obstructive hypertrophic cardiomyopathy
por: Cheddadi L, et al.
Publicado: (2017)

β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity
por: Arjun S. Adhikari, et al.
Publicado: (2019)

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition
por: Julien Robert-Paganin, et al.
Publicado: (2018)

Sudden cardiac death risk in hypertrophic cardiomyopathy: comparison between echocardiography and magnetic resonance imaging
por: Mateusz Śpiewak, et al.
Publicado: (2021)

Selective Interventricular Septal Radiofrequency Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy: Who Can Benefit?
por: Qiang Liu, et al.
Publicado: (2021)

Homeostatic Left Heart integration and disintegration links atrio-ventricular covariation’s dyshomeostasis in Hypertrophic Cardiomyopathy
por: Paolo Piras, et al.
Publicado: (2017)

Conduction abnormalities post alcohol septal ablation for hypertrophic cardiomyopathy – A single center experience
por: Avinash Mani, et al.
Publicado: (2021)

Acute coronary syndrome with non-obstructive coronary arteries (ACS-NOCA) in patients with hypertrophic cardiomyopathy
por: Sarinya Puwanant, et al.
Publicado: (2021)

Relationship Between Obstructive Sleep Apnea and Late Gadolinium Enhancement and Their Effect on Cardiac Arrhythmias in Patients with Hypertrophic Obstructive Cardiomyopathy
por: Wang S, et al.
Publicado: (2021)

Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy.
por: Bianca C Bernardo, et al.
Publicado: (2014)

Comparison of mitral regurgitation severity assessments based on magnetic resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy
por: Mateusz Śpiewak, et al.
Publicado: (2021)

Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure.
por: Richard D Bagnall, et al.
Publicado: (2012)

The Echocardiographic Parameters of Systolic Function Are Associated with Specific Metabolomic Fingerprints in Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy
por: Martino Deidda, et al.
Publicado: (2021)

Characteristics of left atrial remodeling in patients with atrial fibrillation and hypertrophic cardiomyopathy in comparison to patients without hypertrophy
por: Sotirios Nedios, et al.
Publicado: (2021)

Incremental benefit of late gadolinium cardiac magnetic resonance imaging for risk stratification in patients with hypertrophic cardiomyopathy
por: Christina Doesch, et al.
Publicado: (2017)

Blood-based protein profiling identifies serum protein c-KIT as a novel biomarker for hypertrophic cardiomyopathy
por: Kristina Sonnenschein, et al.
Publicado: (2021)

Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction
por: Yumin Li, et al.
Publicado: (2021)

Outcomes in Patients With Obstructive Hypertrophic Cardiomyopathy and Concomitant Aortic Stenosis Undergoing Surgical Myectomy and Aortic Valve Replacement
por: Milind Y. Desai, et al.
Publicado: (2021)